Gemella haemolysans bacteremia in a patient with secondary peritonitis due to a duodenal ulcer perforation: A case report

Changes in Gut Microbiota and Systemic Inflammation after Synbiotic Supplementation in Patients with Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled Trial

Gut dysbiosis has a role in the pathogenesis of lupus. Synbiotic supplementation may restore the balance of gut microbiota. This study investigated whether synbiotics could improve gut microbiota and systemic inflammation in lupus patients. This randomized, double-blind, placebo-controlled trial was conducted in adult systemic lupus erythematosus (SLE) patients. Subjects were randomized to receive either synbiotics or a placebo. Fecal microbiota, hs-CRP, IL-6, and IL-17 were measured at baseline and after 60 days. Patients who fulfilled the inclusion criteria were randomized into synbiotic (n = 23) and placebo groups (n = 23). In the synbiotic group, hs-CRP was not significantly increased (1.8 [0.9; 4.85] vs. 2.1 [0.9; 4.25] mg/L; pre vs. post; p = 0.23), whereas in the placebo group hs-CRP was increased significantly (1.75 [0.4; 4.45] vs. 3.75 [0.58; 7.05] mg/L; pre vs. post; p = 0.005). In the synbiotic group, IL-6 decreased significantly (8.76 [6.62; 11.39] vs. 6.59 [4.96; 8.01]; pre vs. post; p = 0.02), while there was no significant change in IL-17 level. In the placebo group, there was no significant change in IL-6 and IL-17. Synbiotic supplementation increased the Firmicutes:Bacteroidetes ratio (0.05 ± 0.60 vs. -0.08 ± 0.63, synbiotic vs. placebo p = 0.48) and butyrate metabolism (p = 0.037) and decreased amino sugar and nucleotide sugar metabolism (p = 0.040). There was improvement in the SLE disease activity index 2K (SLEDAI-2K) score in the synbiotic group (14 [9; 16] vs. 8 [2; 12]; pre vs. post; p < 0.001), while no change in the placebo group (9 [8; 18.25] vs. 9 [5.5; 15]; pre vs. post; p = 0.31). Synbiotic supplementation could reduce systemic inflammation and SLE disease activity and alter the composition and functions of gut microbiota.

Gemella haemolysans as an emerging pathogen for bacteremia among the elderly

We report a patient of an 82‐year‐old woman with occult Gemella haemolysans bacteremia without a clear entry site. Gemella haemolysans is part of the normal human flora but can cause severe systemic infections such as infective endocarditis on rare occasions. In this patient, physical examination showed no localized symptoms, and a transthoracic echocardiogram showed no vegetation on the heart valves. The entry site for this pathogen was unclear. As the number of the elderly with asymptomatic infections has been increasing, clinicians should be aware of that this microorganism can cause occult bacteremia and infective endocarditis.

A Rare Case of Gemella haemolysans Infection of Knee Arthroplasty

Gemella haemolysans is a facultative, catalase-negative, anaerobic, gram-positive cocci. It is known to mostly cause endocarditis, meningitis, peritonitis, and cerebral abscesses. However, it is extremely rare for this organism to cause infections of an orthopedic nature, with only a single report of infection in total knee arthroplasty (TKA). We present a rare case of knee arthroplasty infection caused by G. haemolysans four years after an uncomplicated TKA procedure.